journal article·2023-08-30Open access

Antibody-Functionalized Polymer Nanoparticles for Targeted Antibiotic Delivery in Models of Pathogenic Bacteria Infecting Human Macrophages

Laura Gabriela Miranda Calderon, Teresa Alejo, Sabas Santos, Gracia Mendoza, Silvia Irusta, Manuel Arruebo

ACS Applied Materials & Interfaces· Volume 15· Issue 34

Abstract

The efficacy of antibody-functionalized poly( d, l -lactide-co-glycolide) (PLGA) nanoparticles (NPs), prepared by nanoprecipitation, carrying rifampicin (RIF) against planktonic, sessile, and intracellular Staphylococcus aureus and Escherichia coli is reported here. A biotinylated anti- S. aureus polyclonal antibody, which binds to structural antigens of the whole bacterium, was functionalized on the surface of RIF-loaded PLGA-based NPs by using the high-affinity avidin–biotin complex. This general strategy allows the binding of commercially available biotinylated antibodies. Coculture models of S. aureus ATCC 25923 and Escherichia coli S17 were used to demonstrate the preferential selectivity of the antibody-functionalized NPs against the Gram-positive bacterium only. At 0.2 μg/mL, complete S. aureus eradication was observed for the antibody-functionalized RIF-loaded NPs, whereas only a 5-log reduction was observed for the nontargeted RIF-loaded NPs. S. aureus is a commensal facultative pathogen having part of its live cycle intracellularly in both phagocytic and nonphagocytic cells. Those intracellular bacterial persisters, named small colony variants, have been postulated as reservoirs of relapsed episodes of infection and consequent treatment failure. At 0.5 μg/mL, the RIF-loaded NPs reduced in 2-log intracellular S. aureus -infecting human macrophages. The ability of those antibody-functionalized nanoparticles to prevent biofilm formation or to reduce the bacterial burden in already-formed mature biofilms is also reported here using S. aureus and E. coli single and cocultured biofilms. In the prevention of S. aureus biofilm formation, the antibody-functionalized NPs exerted a superior inhibition of bacterial growth (up to 2 logs) compared to the nonfunctionalized ones. This study demonstrates the selectivity of the synthesized immunonanoparticles and their antimicrobial efficacy in different scenarios, including planktonic cultures, sessile conditions, and even against intracellular infective pathogens.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Bacterial biofilms and quorum sensing · Antimicrobial Peptides and Activities · Orthopedic Infections and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Instituto de Nanociencia y Materiales de Aragón (INMA), CSIC-Universidad de Zaragoza, Zaragoza 50009, Spain

Department of Chemical Engineering, University of Zaragoza, Campus Río Ebro-Edificio I+D, C/ Poeta Mariano Esquillor S/N, Zaragoza 50018, Spain

Networking Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, Madrid 28029, Spain

Aragon Health Research Institute (IIS Aragon), Zaragoza 50009, Spain

Funding

European Commission · European Regional Development Fund · Ministerio de Ciencia e Innovaci?n · Consejo Nacional de Ciencia y Tecnolog?a · Instituto de Salud Carlos III

References (46)

Show source-provided references
1. 10.1128/MICROBIOLSPEC.VMBF-0016-201510.1128/MICROBIOLSPEC.VMBF-0016-2015 ↗
2. 10.1089/MDR.2018.031910.1089/MDR.2018.0319 ↗
3. 10.1038/s41579-020-0420-110.1038/s41579-020-0420-1 ↗
4. 10.3390/APP11221069510.3390/APP112210695 ↗
5. 10.1128/CMR.00134-1410.1128/CMR.00134-14 ↗
6. 10.1021/acsami.6b0752810.1021/acsami.6b07528 ↗
7. 10.1021/acs.analchem.8b0479210.1021/acs.analchem.8b04792 ↗
8. 10.1016/J.BIOMATERIALS.2014.04.09210.1016/J.BIOMATERIALS.2014.04.092 ↗
9. 10.1007/s10439-012-0698-x10.1007/s10439-012-0698-x ↗
10. 10.1080/02656736.2017.139204710.1080/02656736.2017.1392047 ↗
11. 10.1016/J.JPHOTOBIOL.2018.04.03710.1016/J.JPHOTOBIOL.2018.04.037 ↗
12. 10.1038/S41551-017-0187-510.1038/S41551-017-0187-5 ↗
13. 10.1021/acs.biomac.1c0008210.1021/acs.biomac.1c00082 ↗
14. 10.1038/nature1605710.1038/nature16057 ↗
15. 10.1016/J.TIM.2008.11.00410.1016/J.TIM.2008.11.004 ↗
16. 10.3389/FCIMB.2012.0004310.3389/FCIMB.2012.00043 ↗
17. 10.1038/s41467-020-15966-710.1038/s41467-020-15966-7 ↗
18. 10.1128/CMR.14.2.244-269.200110.1128/CMR.14.2.244-269.2001 ↗
19. 10.1016/S0140-6736(05)70155-010.1016/S0140-6736(05)70155-0 ↗
20. 10.1093/FEMSPD/FTW01910.1093/FEMSPD/FTW019 ↗
21. 10.2147/DDDT.S13888810.2147/DDDT.S138888 ↗
22. 10.1016/J.BIOMATERIALS.2007.08.01110.1016/J.BIOMATERIALS.2007.08.011 ↗
23. 10.3390/NANO1106155910.3390/NANO11061559 ↗
24. 10.1016/J.JPHOTOCHEM.2017.11.00610.1016/J.JPHOTOCHEM.2017.11.006 ↗
25. 10.1021/acsami.6b1512310.1021/acsami.6b15123 ↗
26. 10.1081/DDC-10010836410.1081/DDC-100108364 ↗
27. 10.3390/POLYM1204082310.3390/POLYM12040823 ↗
28. 10.3390/POLYM1309151410.3390/POLYM13091514 ↗
29. 10.1016/J.JDDST.2022.10343510.1016/J.JDDST.2022.103435 ↗
30. 10.1016/J.COLSURFB.2004.03.01810.1016/J.COLSURFB.2004.03.018 ↗
31. 10.1073/PNAS.150974311210.1073/PNAS.1509743112 ↗
32. 10.1021/acs.molpharmaceut.0c0040810.1021/acs.molpharmaceut.0c00408 ↗
33. 10.1016/B978-1-4160-3291-5.50085-810.1016/B978-1-4160-3291-5.50085-8 ↗
34. 10.1002/ADVS.20200137410.1002/ADVS.202001374 ↗
35. 10.1128/mBio.00043-1110.1128/mBio.00043-11 ↗
36. 10.1016/J.JCOT.2019.10.00210.1016/J.JCOT.2019.10.002 ↗
37. 10.1155/2014/25069410.1155/2014/250694 ↗
38. 10.1093/JAC/DKAB48610.1093/JAC/DKAB486 ↗
39. 10.1016/J.DIAGMICROBIO.2012.05.03410.1016/J.DIAGMICROBIO.2012.05.034 ↗
40. 10.1038/S41598-018-21141-210.1038/S41598-018-21141-2 ↗
41. 10.1128/MICROBIOLSPEC.MB-0011-201410.1128/MICROBIOLSPEC.MB-0011-2014 ↗
42. 10.1186/s12866-018-1182-z10.1186/s12866-018-1182-z ↗
43. UNE-EN ISO 10993-5:2009 Evaluación Biológica de Productos Sani. https://www.une.org/encuentra-tu-norma/busca-tu-norma/norma/?Tipo=N&c=N0044389. (Accessed 2023-02-28).
44. 10.1021/acsami.7b1481210.1021/acsami.7b14812 ↗
45. 10.2217/NNM-2017-024810.2217/NNM-2017-0248 ↗
46. 10.1080/1388020059095182910.1080/13880200590951829 ↗